Showing results (51-60 of 137) with videos related to
Sort By:
Pageof 14
The Journal of Infectious Diseases|July 28, 2011
Antiviral activity of danoprevir (ITMN-191/RG7227) in combination with pegylated interferon α-2a and ribavirin in patients with hepatitis CNicole Forestier, Dominique Larrey, Patrick Marcellin, et al.Liver International : Official Journal of the International Association for the Study of the Liver|December 10, 2014
Incidence of solid organ cancers after liver transplantation: comparison with regional cancer incidence rates and risk factorsChristophe Carenco, Stéphanie Faure, Astrid Herrero, et al.Journal of Viral Hepatitis|February 11, 2019
Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countriesPeter Ferenci, Stefan Bourgeois, Peter Buggisch, et al.Gastrointestinal Endoscopy|November 5, 2003
Are drugs a risk factor of post-ERCP pancreatitis?Pascal Perney, Emile Berthier, Georges-Philippe Pageaux, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 21, 2011
Education by a nurse increases response of patients with chronic hepatitis C to therapy with peginterferon-α2a and ribavirinDominique Larrey, Annie Salse, Didier Ribard, et al.Journal of Tissue Engineering and Regenerative Medicine|November 7, 2017
Mesenchymal stem cells seeded on a human amniotic membrane improve liver regeneration and mouse survival after extended hepatectomyAure Despeyroux, Cédric Duret, Claire Gondeau, et al.Transplant International : Official Journal of the European Society for Organ Transplantation|October 14, 2005
Are preoperative patterns of alcohol consumption predictive of relapse after liver transplantation for alcoholic liver disease?Pascal Perney, Michaël Bismuth, Hélène Sigaud, et al.Journal of Hepatology|March 22, 2014
Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141)Sylvie Deuffic-Burban, Michaël Schwarzinger, Dorothée Obach, et al.Journal of Hepatology|November 10, 2012
Clinical management of drug-drug interactions in HCV therapy: challenges and solutionsDavid Burger, David Back, Peter Buggisch, et al.Clinical Chemistry|October 24, 2007
Global sequencing approach for characterizing the molecular background of hereditary iron disordersSéverine Cunat, Muriel Giansily-Blaizot, Michael Bismuth, et al.Pageof 14